Gordon advised the shareholders of DB Ashbourne, a provider of off-patent branded pharmaceuticals for the UK market, on their sale to Ethypharm S.A, a French company with an international presence which develops innovative pharmaceutical products.
I am very pleased to have found such a complementary match in Ethypharm, a highly successful manufacturer of sustained release drugs with an established history of drug development.
.svg)
